Recursion Pharmaceuticals, Inc. RXRX
We take great care to ensure that the data presented and summarized in this overview for RECURSION PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RXRX
View all-
Vanguard Group Inc Valley Forge, PA39.8MShares$165 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl33.5MShares$139 Million1.15% of portfolio
-
Baillie Gifford & CO24MShares$99.3 Million0.09% of portfolio
-
State Street Corp Boston, MA18.3MShares$75.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$71.7 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$60.7 Million0.3% of portfolio
-
Kinnevik Ab (Publ) Stockholm, V713.4MShares$55.6 Million100.0% of portfolio
-
Mic Capital Management Uk LLP London, X09.64MShares$39.9 Million12.03% of portfolio
-
Geode Capital Management, LLC Boston, MA9.62MShares$39.8 Million0.0% of portfolio
-
Novo Holdings Hellerup, G77.93MShares$32.8 Million3.13% of portfolio
Latest Institutional Activity in RXRX
Top Purchases
Top Sells
About RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Insider Transactions at RXRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2026
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
220,000
-3.2%
|
$880,000
$4.36 P/Share
|
|
Jan 05
2026
|
Christopher Gibson Director |
SELL
Bona fide gift
|
Direct |
20,000
-2.14%
|
-
|
|
Jan 05
2026
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
40,000
-4.11%
|
$160,000
$4.25 P/Share
|
|
Jan 05
2026
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
60,000
+5.8%
|
-
|
|
Jan 02
2026
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,381
+0.19%
|
-
|
|
Jan 02
2026
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,571
+2.45%
|
-
|
|
Dec 29
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
21,383
-2.73%
|
$85,532
$4.18 P/Share
|
|
Dec 22
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Open market or private sale
|
Direct |
124,403
-16.91%
|
$497,612
$4.41 P/Share
|
|
Dec 19
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
40,000
-4.19%
|
$160,000
$4.5 P/Share
|
|
Dec 19
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
40,000
+4.02%
|
-
|
|
Dec 15
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,057
-0.89%
|
$28,228
$4.33 P/Share
|
|
Dec 04
2025
|
Christopher Gibson Director |
SELL
Bona fide gift
|
Direct |
20,000
-2.14%
|
-
|
|
Dec 04
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
40,000
-4.11%
|
$160,000
$4.63 P/Share
|
|
Dec 04
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
60,000
+5.8%
|
-
|
|
Dec 02
2025
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
220,000
-3.1%
|
$880,000
$4.37 P/Share
|
|
Nov 25
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,271
-0.29%
|
$9,084
$4.03 P/Share
|
|
Nov 19
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
40,000
-4.19%
|
$160,000
$4.16 P/Share
|
|
Nov 19
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
40,000
+4.02%
|
-
|
|
Nov 17
2025
|
Christopher Gibson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
40,390
-4.23%
|
$161,560
$4.14 P/Share
|
|
Nov 17
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,584
-2.33%
|
$70,336
$4.14 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.12M shares |
|---|---|
| Conversion of derivative security | 1.42M shares |
| Open market or private sale | 2.16M shares |
|---|---|
| Payment of exercise price or tax liability | 278K shares |
| Bona fide gift | 110K shares |